Close
ALS Reversals – an update

ALS Reversals – an update

Reading Time: 10 minutes For the purposes of this blog, ALS should be taken to mean ALS/MND. In September 2020 we published a blog article discussing Dr Rick Bedlack’s unique perspective on ALS reversals. This followed a webinar in which Dr Bedlack presented potential evidence of 48 people around the world who had a confirmed diagnosis of ALS, some…

Risk of death – clinical trial statistics explained

Risk of death – clinical trial statistics explained

Reading Time: 5 minutes "New drug reduces risk of death by 50%"

You may have seen this type of headline in news articles reporting on the outcome of clinical trials. Reading this headline can lead people to believe a potential drug is highly beneficial and has a real impact. However, it is important to delve a little deeper into the meaning of ‘risk of death’, the raw data behind it, and how it should be considered alongside other outcome measures of a trial to fully determine how effective a drug might be.

How can technology and telemedicine play a role in MND care and research?

How can technology and telemedicine play a role in MND care and research?

Reading Time: 5 minutes Hi, my name is Avril Mc Tague. I am undertaking a Ph.D. at Trinity College, Dublin, Ireland as part of the Multidisciplinary Innovation and Research Advancing Neurological care in a Digital Age (MIRANDA) doctoral award programme. This is funded by the Health Research Board in Ireland. I was one of five symposium communication ambassadors at last year’s international symposium.

Reuniting the MND community at the 34th International Symposium on ALS/MND

Reuniting the MND community at the 34th International Symposium on ALS/MND

Reading Time: 4 minutes After 3 years of online events, the MND research and healthcare community reunited in-person at the 34th International Symposium on ALS/MND in Basel, Switzerland! From 6 – 8 December 2023, we welcomed back over 1300 delegates, including researchers, health and social care professionals and people living with and affected by MND, becoming one of our…

Symposium Preview: Meet the ALS/FTD Plenary Speakers…Part 2

Symposium Preview: Meet the ALS/FTD Plenary Speakers…Part 2

Reading Time: 5 minutes Every year, the team works hard to build on the previous year’s success. This year we are excited to include a series of three ALS-FTD joint sessions, in collaboration with the International Society for Frontotemporal Dementias, in the programme. To give you a teaser of what is to come, we are taking a closer look at the plenary speakers in the ALS-FTD sessions at the Symposium. In this blog, we explore the topics they will be presenting and find out a little more about the speakers.

Symposium Preview: Meet the Symposium Communications Ambassadors

Symposium Preview: Meet the Symposium Communications Ambassadors

Reading Time: 7 minutes Each year at the Symposium, there is a huge amount of research presented on a range of topics from across the globe. With the Symposium returning to an in-person event this year, we are keen to increase the number of updates we share for those not able to attend, including people living with and affected by MND.

To help us do this, we have launched a new Symposium Communications Ambassador Programme so we can bring more of the research from the Symposium to non-scientific audiences. This programme was open for applications from early career researchers working in MND, who were interested in helping us shine a light on MND research happening across the world. This year we have 5 early career researchers taking part in the Programme, who will gain experience and new skills in communicating research to different audiences. Before, during and after the Symposium our Ambassador’s will be helping us to share the latest research with the MND community.